Alan D. D’Andrea
Impact in
- Cancer Research top 0.05%
- Carcinogens and Genotoxicity Assessment
- Oncology top 0.05%
- PARP inhibition in cancer therapy
- Cancer-related Molecular Pathways
Papers in
-
- DNA Repair Mechanisms 184
- CRISPR and Genetic Engineering 54
- Ubiquitin and proteasome pathways 36
- Genomics and Chromatin Dynamics 28
- Oncology 119
- PARP inhibition in cancer therapy 69
- Cancer-related Molecular Pathways 27
- Co-authors
- Toshiyasu Taniguchi (20 shared papers)Raphaël Ceccaldi (11 shared papers)Markus Grompe (15 shared papers)Panagiotis A. Konstantinopoulos (25 shared papers)Beatrice Rondinelli (2 shared papers)Gordon Wong (3 shared papers)Paul R. Andreassen (6 shared papers)Geoffrey I. Shapiro (42 shared papers)
- Journals
- Blood (38 papers)Molecular and Cellular Biology (28 papers)Cancer Research (21 papers)Molecular Cell (19 papers)Proceedings of the National Academy of Sciences (16 papers)
- Partner nations
- United StatesUnited KingdomGermany
In The Last Decade
Alan D. D’Andrea
312 papers receiving 32.6k citations
Alan D. D’Andrea's Hit Papers
Peers
Comparison fields: 5 of 146
- Cancer Research 6.2k
- Oncology 10.7k
- Molecular Biology 24.5k
- Hematology 2.4k
- Genetics 4.8k
Countries citing papers authored by Alan D. D’Andrea
This map shows the geographic impact of Alan D. D’Andrea's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan D. D’Andrea with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan D. D’Andrea more than expected).
Fields of papers citing papers by Alan D. D’Andrea
This network shows the impact of papers produced by Alan D. D’Andrea. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan D. D’Andrea. The network helps show where Alan D. D’Andrea may publish in the future.
Co-authors
The 25 scholars most cited alongside Alan D. D’Andrea, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 315 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Repair Pathway Choices and Consequences at the Double-Strand Break Hit paper breakdown → | 2015 | 1111 |
| 2 | Interaction of the Fanconi Anemia Proteins and BRCA1 in a Common Pathway Hit paper breakdown → | 2001 | 983 |
| 3 | Biallelic Inactivation of BRCA2 in Fanconi Anemia Hit paper breakdown → | 2002 | 860 |
| 4 | Cloning of cDNA for the major DNA-binding protein of the erythroid lineage through expression in mammalian cells Hit paper breakdown → | 1989 | 851 |
| 5 | Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair Hit paper breakdown → | 2015 | 663 |
| 6 | The Fanconi anaemia/BRCA pathway Hit paper breakdown → | 2003 | 656 |
| 7 | Expression cloning of the murine erythropoietin receptor Hit paper breakdown → | 1989 | 654 |
| 8 | Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer Hit paper breakdown → | 2015 | 631 |
| 9 | Identification of the FANCI Protein, a Monoubiquitinated FANCD2 Paralog Required for DNA Repair Hit paper breakdown → | 2007 | 559 |
| 10 | Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1 Hit paper breakdown → | 2015 | 525 |
| 11 | The Fanconi anaemia pathway: new players and new functions Hit paper breakdown → | 2016 | 502 |
| 12 | DNA Damage and Repair Biomarkers of Immunotherapy Response Hit paper breakdown → | 2017 | 495 |
| 13 | 2006 | 475 | |
| 14 | 2005 | 466 | |
| 15 | Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer Hit paper breakdown → | 2016 | 456 |
| 16 | 2009 | 455 | |
| 17 | 2013 | 448 | |
| 18 | 1996 | 432 | |
| 19 | 2003 | 431 | |
| 20 | 2012 | 403 |
About Alan D. D’Andrea
Alan D. D’Andrea is a scholar working on Molecular Biology, Oncology, Cancer Research, Genetics and Hematology, having authored 315 papers that have together received 33.1k indexed citations. Recurring topics across this work include DNA Repair Mechanisms (184 papers), PARP inhibition in cancer therapy (69 papers), CRISPR and Genetic Engineering (54 papers), Carcinogens and Genotoxicity Assessment (47 papers), Ubiquitin and proteasome pathways (36 papers), Genomics and Chromatin Dynamics (28 papers), Cancer-related Molecular Pathways (27 papers) and BRCA gene mutations in cancer (25 papers). The work is most often cited by research in Cancer Research (6.2k citations), Oncology (10.7k citations), Molecular Biology (24.5k citations), Hematology (2.4k citations) and Genetics (4.8k citations). Alan D. D’Andrea has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Toshiyasu Taniguchi, Raphaël Ceccaldi, Markus Grompe, Panagiotis A. Konstantinopoulos, Beatrice Rondinelli, Gordon Wong, Paul R. Andreassen, Geoffrey I. Shapiro, Younghoon Kee and Irene García-Higuera. Their work appears in journals such as Blood, Molecular and Cellular Biology, Cancer Research, Molecular Cell and Proceedings of the National Academy of Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.